17780-72-2
Chemical Structure
Clorgyline
Synonym(s): M&B 9302
- CAS No.: 17780-72-2
- Formula:C13H15Cl2NO
- Molecular Weight:272.17
IUPAC Name: N-(3-(2,4-dichlorophenoxy)propyl)-N-methylprop-2-yn-1-amine
InChIKey: BTFHLQRNAMSNLC-UHFFFAOYSA-N
SMILES: ClC1=CC=C(C(Cl)=C1)OCCCN(CC#C)C
Biological Activity: Clorgyline (M&B 9302) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Clorgyline | 99.76% | Clorgyline (M&B 9302) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177-98. [Content Brief]
- [2]. Zhao H, et al. Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC medical genomics. 2009 Aug 20;2:55.
- [3]. Garcia-Miralles M, et al. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental neurology. 2016 Apr;278:4-10.
- [4]. Ross RJ, et al. The effect of clorgyline on noradrenergic function. Psychopharmacology. 1985;85(2):227-30.
- [5]. Seymour CB, et al. Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. British journal of cancer. 2003 Nov 17;89(10):1979-86. [Content Brief]
- [6]. Tamarkin L, et al. Effect of clorgyline (a MAO type A inhibitor) on locomotor activity in the Syrian hamster. The American journal of physiology. 1983 Aug;245(2):R215-21.
- [7]. Feldman JM, et al. Effect of the monoamine oxidase inhibitors clorgyline and pargyline on the hyperphagia of obese mice. Behavioural brain research. 1988 Jul;29(1-2):147-58. [Content Brief]
- [8]. Campbell IC, et al. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem. 1979 Jan;32(1):49-55. [Content Brief]
- [9]. Green AR, et al. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. British journal of pharmacology. 1975 Nov;55(3):415-22. [Content Brief]
